Cutaneous Squamous Cell

Expanded Access Program
Not candidates for surgery prior to Cemiplimab being commercially available

SKIN0041
Expanded Access Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
PI: Chang
Sponsor: Pending

Previously treated with Platinum or Cetuximab continuing regimen

SKIN0039
Phase II Pembrolizumab in Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)
PI: Chang
Marck Sharp & Doehme

KEY
- Pending
- Open for Enrollment
- Optional Path
- Extension Study
- Immunotherapy
- Link
- Trial Posting
- Enrollment on Hold